These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 25245263)
1. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Zhan X; Jia L; Niu Y; Qi H; Chen X; Zhang Q; Zhang J; Wang Y; Dong L; Wang C Biomaterials; 2014 Dec; 35(38):10046-57. PubMed ID: 25245263 [TBL] [Abstract][Full Text] [Related]
2. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Wang Y; Lin YX; Qiao SL; An HW; Ma Y; Qiao ZY; Rajapaksha RP; Wang H Biomaterials; 2017 Jan; 112():153-163. PubMed ID: 27768970 [TBL] [Abstract][Full Text] [Related]
3. A tumour microenvironment-responsive polymeric complex for targeted depletion of tumour-associated macrophages (TAMs). Wang Y; Guo G; Feng Y; Long H; Ma DL; Leung CH; Dong L; Wang C J Mater Chem B; 2017 Sep; 5(35):7307-7318. PubMed ID: 32264180 [TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259 [TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of Zoledronate to Tumor-Associated Macrophages for Cancer Immunotherapy. Zang X; Zhang X; Hu H; Qiao M; Zhao X; Deng Y; Chen D Mol Pharm; 2019 May; 16(5):2249-2258. PubMed ID: 30969779 [TBL] [Abstract][Full Text] [Related]
6. Molecular Repolarisation of Tumour-Associated Macrophages. van Dalen FJ; van Stevendaal MHME; Fennemann FL; Verdoes M; Ilina O Molecules; 2018 Dec; 24(1):. PubMed ID: 30577495 [TBL] [Abstract][Full Text] [Related]
7. IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma. Tan HY; Wang N; Tsao SW; Che CM; Yuen MF; Feng Y Oncotarget; 2016 Jul; 7(28):43792-43804. PubMed ID: 27270308 [TBL] [Abstract][Full Text] [Related]
8. Using macrophage activation to augment immunotherapy of established tumours. Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183 [TBL] [Abstract][Full Text] [Related]
10. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy. Wang Y; Luan Z; Zhao C; Bai C; Yang K Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343 [TBL] [Abstract][Full Text] [Related]
11. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Ngambenjawong C; Gustafson HH; Pun SH Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873 [TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. Huang Z; Gan J; Long Z; Guo G; Shi X; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L Biomaterials; 2016 Jun; 90():72-84. PubMed ID: 26994345 [TBL] [Abstract][Full Text] [Related]
13. Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy. Zang X; Zhang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D Mol Pharm; 2019 Apr; 16(4):1714-1722. PubMed ID: 30860846 [TBL] [Abstract][Full Text] [Related]
14. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy. Xu L; Xie X; Luo Y Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912 [TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages as an antitumor strategy. Cheng N; Bai X; Shu Y; Ahmad O; Shen P Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498 [TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. Huang Z; Zhang Z; Jiang Y; Zhang D; Chen J; Dong L; Zhang J J Control Release; 2012 Mar; 158(2):286-92. PubMed ID: 22119956 [TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages: role in cancer development and therapeutic implications. Salmaninejad A; Valilou SF; Soltani A; Ahmadi S; Abarghan YJ; Rosengren RJ; Sahebkar A Cell Oncol (Dordr); 2019 Oct; 42(5):591-608. PubMed ID: 31144271 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. Xu M; Liu M; Du X; Li S; Li H; Li X; Li Y; Wang Y; Qin Z; Fu YX; Wang S J Immunol; 2015 May; 194(10):4997-5006. PubMed ID: 25876763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]